Abstract: The present invention relates to a pharmaceutical composition for suppressing obesity or lowering blood sugar which comprises Cudrania tricuspidata extract and Coix lachryma-jobi extract, and more specifically relates to a pharmaceutical composition for suppressing obesity or lowering blood sugar which comprises Cudrania tricuspidata extract and Coix lachrymajobi extract, to a functional health food or food additive composition for suppressing obesity or lowering blood sugar which comprises Cudrania tricuspidata extract and Coix lachryma-jobi extract, to a tablet having an obesity-suppressing function and blood-sugar lowering effect which is produced using Cudrania tricuspidata and Coix lachryma-jobi as principal raw materials, and to a production method therefor.

Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.

Abstract: This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.

Abstract: Microcapsules containing an active ingredient, constituted by a core coated with a polymer membrane, characterized in that the active ingredient is incorporated in the polymer coating layer, and in that said layer is applied using microencapsulation techniques (coacervation by means of phase separation). The microcapsules; thus produced have excellent properties of taste masking and prolonged release of the active ingredients.

Abstract: The present invention relates to a process for treating sol-gel capsules comprising a cosmetic or pharmaceutical active material with an inorganic material, as well as sol-gel capsules produced by a process according to the present invention and formulations comprising such sol-gel capsules.

Abstract: A non-porous dental wedge having a surface coating of a material for aiding a dental procedure. A thin coating of an adhesive and particles having a particle size less than 200 microns is placed on the surface of the non-porous dental wedge. The material is preferable an astringent. The non-porous dental wedge is resistant to compression and the thin surface coating with small material particle size facilitates rapidly disperses the material during a dental procedure.

Abstract: The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression.

Abstract: A method of polymerising monomer to form polymer at the surface of particulate material, said method comprising: providing a dispersion of said particulate material in a continuous liquid phase, said dispersion comprising a RAFT agent as a stabiliser for said particulate material, and said continuous liquid phase comprising one or more ethylenically unsaturated monomers; and polymerising said one or more ethylenically unsaturated monomers under the control of said RAFT agent to thereby form polymer at the surface of said particulate material.

Abstract: Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.

Abstract: The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid medium comprising at least one organic or inorganic compound which is to be solidified, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s).

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively.

Abstract: The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with increased interleukin-1? and/or interleukin-6 and/or interleukin-8 activity and/or that can be treated by lowering said cytokine activity.

Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a process for coating a particle comprising a pharmaceutically active ingredient (API) comprising the steps of providing a composition comprising carbonate ions, phosphate ions, or a mixture thereof, providing a particle comprising an API, and precipitating a carbonate salt, a phosphate salt or a mixture thereof onto said particles. The present invention is also directed to a particle comprising an API, wherein the particle is coated with a coating comprising a carbonate salt, phosphate salt, or mixture thereof, and to a pharmaceutical composition comprising said particles.

Abstract: An enteric coating composition including about 0.01% to about 10% resin and about 0.01% to about 10% polymer. The enteric coating composition may be applied to a substrate, such as a pharmaceutical, nutraceutical, fruit, vegetable, agricultural product, or industrial product, to form an enteric coating on the substrate. Also provided is a multiple-component system having a first component including a resin and a second component including a polymer, wherein mixing the first component and the second component forms an enteric coating composition having about 0.01% to about 10% resin and about 0.01% to about 10% polymer. Methods for coating a substrate with the enteric coating compositions are also provided.

Abstract: The present invention relates to a silicon-containing, biodegradable material for preventing and/or treating diseases that are associated with reduced and/or disturbed angiogenesis and/or diseases for which an increased rate of angiogenesis is beneficial to the healing process.

Abstract: Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.

Abstract: The invention relates to the fields of polymer chemistry, pharmacy and medicine and relates to a method, which for example releases drugs as a component of implants into the environment of the implant. The object of the present invention is to disclose a method which in a simple and easily reproducible manner generates a drug delivery system, which releases drugs in a locally targeted and controllably delayed manner. The object is attained by a method in which polyanions and polycations are mixed in a liquid in a non-stoichiometric ratio, relative to the charged monomer units, wherein drugs are added to the polyelectrolytes either before, during or after the mixing, or charge-carrying drugs and an oppositely charged polyelectrolyte are mixed, and after the mixing the polyelectrolyte complex produced is applied to the surface of a medical means or is positioned on the surface directly at the location where the drug is to be released.

Abstract: The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis.

Abstract: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising droplets of said discontinuous phase, allowing nanoparticles to congregate at the phase interface at the surface of the droplets such that at least one layer of nanoparticles coat the droplets and thereby provide sufficient structural integrity to the droplets to enable the subsequent removal of the continuous phase, and thereafter removing the continuous phase from the nanoparticle-coated droplets to produce a dried formulation.

Abstract: An apparatus and method for supporting a tubular medical device, such as a stent or scaffold, includes a rod disposed between two collets. The rod can be shaped to form a range of different size or length helical supports to support a wide range of tubular medical devices. The rod is shaped into a full or partial helix by rotating one of the collets relative to the other.

Abstract: The present invention relates to a composition for nucleic acid delivery and a method for preparing the same, more particularly to a composition for nucleic acid delivery having excellent stability in the body environment and excellent intracellular delivery efficiency of nucleic acid, and enabling target directed delivery of nucleic acid, and a method for preparing the same.

Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.

Abstract: This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.

Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.

Abstract: The present invention pertains to therapeutic compositions and delivery systems comprising at least one microparticle or nanoparticle. In various embodiments, the surface of the microparticle or nanoparticle is modified or functionalized with at least a portion of an isolated cellular membrane, such as an isolated plasma membrane. In addition, the microparticle or nanoparticle contains at least one active agent, such as a therapeutic and/or imaging agent. In additional embodiments, the compositions and delivery systems of the present invention may be used for targeted delivery of an active agent. Also provided are methods of making the therapeutic compositions and delivery systems of the present invention.

Abstract: The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder.

Abstract: The disclosure relates to substantially uniform, high density microspheres and methods of making the microspheres. The microspheres can be made to be small in size with a narrow range of particle size distribution and a high sphericity. In one aspect, the microspheres provided herein are provided in the form of spherical cores comprising maltodextrin or maltodextrin and starch and are prepared using a centrifugal tumbling-granulating-coating apparatus. In another aspect, the spherical cores can be powder-coated with one or more layers of small particles, such as starch particles. The microspheres provided herein can be used as cores for multi-particulate solid dosage delivery systems as well as other pharmaceutical, nutraceutical, food, personal care, and other applications.

Abstract: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.

Abstract: A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-erodible doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached.

Abstract: Pharmaceutical formulation based on ibuprofen and codeine having improved stability. The invention consists of a novel pharmaceutical formulation having the form of tablets or similar comprising a core composed of an association of ibuprofen and codeine as active ingredients, together with an excipient including at least a diluent, a disintegrating agent, a fluidizing agent and a lubricant which is sodium stearyl fumarate. Said core is coated with a composition based on one or several polymers of diverse modified cellulose ethers and polymers derived from acrylic and methacrylic acids, a plasticiser and, an opacifier or colouring agent and any of the mixtures thereof. These characteristics render the tablets of the invention more efficacious and safe having the form of more stable preparations, without this fact implying greater technological complexity.

Abstract: This invention is related to a device for the manufacture of a dosage form with a hole and method of manufacture. The dosage form may be a modified release dosage form comprising a core coated with a polymeric coat comprising one or more rate controlling polymers, said dosage form having a hole extending through the dosage form resulting in an inner radial surface and an outer radial surface, said core comprising at least one therapeutically active ingredient, characterized in that the inner radial surface is partially coated with said polymeric coat.

Abstract: The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose.

Abstract: The present invention is directed to film coating compositions for use on oral dosage forms such as compressed tablets and other orally-ingestible substrates which contain a fine particle size detackifier. The film coating compositions can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either polyvinyl alcohol or a copolymer of polyvinyl alcohol. Aqueous suspensions comprising the inventive film coating compositions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.

Abstract: A hard coated confectionary product having a consumable, soft, high solids chewy core fortified with heat sensitive medicaments and vitamins with the core encapsulated in a hard consumable coating and a method for making the fortified confectionary is described.

Abstract: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.

Abstract: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises a drug (5a), wherein the drug effects at least one of the biological regulation of at least one oocyte containing follicle, stimulation of follicle growth, induction of ovulation, promotion of gestational status, maintenance of conceptus, maintenance of pregnancy.

Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.

Abstract: In order to provide an improved powder coating process using gelatin particles for the production of coatings or shaped bodies based on gelatin, it is proposed that the gelatin particles are produced by drying an aqueous gelatin solution, wherein the gelatin does not pass through a gel state before or during the drying.

Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

Abstract: The present disclosure provides a textured dilatation balloon that includes a balloon body having a proximal end, a distal end, and at least one indentation in the balloon body in an un-inflated state, wherein the balloon body comprises a continuous polymer tube with an external surface having at least one therapeutic agent disposed within the at least one indentation.

Abstract: Disclosed are improved granular pharmaceutical preparations, together with improved methods and apparatus for preparation of granules for use in such preparations. Such methods are especially useful for making granules for solid oral dose pharmaceutical preparations, and are particularly suited to the production of granules comprising 5-aminosalicylic acid (5-ASA) for the treatment of inflammatory bowel disease. The granules exhibit a more sharply peaked length distribution, and hence aspect ratio distribution, and have a consequently much sharper dissolution profile after further processing.

Abstract: A drug delivery system which comprises alginate tube that is prepared by coating a substrate with alginate gel. One or more therapeutic drugs may also be present in the alginate gel or in the cavity of the tube. The activity of the alginate drug delivery system is highly adjustable so that the release may be controlled as required. The rate at which the system releases the drug and the concentration of the drug released can be adjusted by varying; the number of layers of the alginate tubes, the number of open or closed ends of the tubes, or the number of tube layers containing the drug.

Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Abstract: An encapsulated chlorine dioxide generator is provided. The encapsulated generator includes a core particle that includes a metal chlorite and a solid acid. The encapsulated generator also includes a protective layer that is disposed about at least a portion of the core particle. The protective layer includes a copolymer of polyvinyl alcohol and a polyalkylene glycol. The encapsulated generator is formed in a method including the steps of forming the core particle and disposing the protective layer about the core particle. The encapsulated generator is also used in a method of cleaning an environment. The method of cleaning the environment includes the steps of providing the encapsulated generator and forming chlorine dioxide from the encapsulated chlorine dioxide generator to clean the environment.

Abstract: Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.

Abstract: The present invention relates to a method for production of a coated preparation, characterized by coating a core material with a coating solution, the core material comprising an active ingredient, the coating solution comprising a) a resin composition obtained by copolymerization of polyvinyl alcohol having an average polymerization degree of 1300 or less, and at least one polymerizable vinyl monomer in a weight ratio of 6:4 to 9:1, b) water, and c) an organic solvent. The method for production make it feasible to efficiently coat a preparation such as a tablet, a granule, and a fine granule, etc. (a pharmaceutical drug, an animal drug, an agricultural chemicals, a fertilizer, or a food product) with the coating solution comprising a) the composition comprising the polyvinyl alcohol copolymer as the main component, b) water, and c) the organic solvent.

Abstract: The present invention is directed ?-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an ?-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the ? emissions from the ?-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the ?-emitting radioisotope from exiting the ?-particle emitting nanoparticle. Further, such ?-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed.

Abstract: Water soluble meloxicam granules comprising: (a) meloxicam; (b) a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam; (c) a binder; (d) a sugar or sweetener; and (e) a carrier, and optionally a flavoring agent and optionally other excipients, processes for preparing them and their use for treating respiratory or inflammatory complaints in mammals.

Abstract: Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV.